Genesis Research and Syapse combine forces to offer RWE and data to oncology innovators
September 2, 2022 | RWE, biomarkers, oncology, partnership, real world data, real-world evidence, rwd
Genesis Research is delighted to announce a strategic partnership with Syapse®, combining the expertise and resources of both companies to better serve clients that are developing new oncology innovations.
Genesis Research is delighted to announce a strategic partnership with Syapse®, a leading real-world evidence company dedicated to extinguishing the fear and burden of serious diseases by advancing real-world care, combining the expertise and resources of both companies to better serve clients developing new oncology innovations. Pharmaceutical and biotech companies partner with Genesis Research to conduct real-world evidence-based research that supports the development and launch of new and innovative treatments.
The new partnership will enable Genesis Research clients in the oncology space, especially those exploring biomarker therapies, to leverage Syapse’s leading real-world evidence platform, enabling them to develop a deeper understanding of these challenging and complex oncological diseases. Concurrently, this strategic relationship will enable Syapse to provide its clients with streamlined access to Genesis’ unique, integrated, fit-for-purpose research partnerships.
“The pharmaceutical leaders we work with increasingly see the value that real-world evidence can bring to the process of developing and launching new treatments that make meaningful differences in the lives of patients,” said Frank A. Corvino, Co-founder and CEO of Genesis Research. “We’re excited to partner with Syapse, who can offer our clients a holistic view of the patient journey through their capture of real-world data in the oncology space, where we’ve come to understand the unique and varied ways that cancer presents in individual patients, as well as the potential role that biomarkers can play in diagnosing and treating these diseases more effectively.”
By partnering with Syapse, Genesis Research clients will have readily available access to an unparalleled real-world data source and powerful analytics tools to gain new insights to support advancement of novel oncology therapies. Syapse’s oncology platform collects, standardizes, and curates available data from a diverse pool of oncology patients, allowing researchers to generate real-world insights on cancer trends and treatments in a real-world setting. Similarly, Syapse’s clients will now be able to benefit from Genesis Research’s agility-focused partnership model and extensive experience in delivering real-world evidence, informed by its comprehensive strategic planning, insight generation and value demonstration products and services.
“Syapse and Genesis Research are a fantastic complement to each other’s strengths, focuses, and missions,” said Ken Tarkoff, CEO of Syapse. “Together, we can offer our respective customers easier access to services, information, and experience that can make the difference when it comes to delivering new, safe, and effective treatments for cancer, using the very latest insights into biomarkers to deliver personalized, tailored care.”
Genesis Research and Syapse look forward to collaborating under this new partnership agreement in the coming weeks and months as both companies begin offering new, co-marketed services to clients.
Further information:
About Syapse
Syapse is a company dedicated to extinguishing the fear and burden of oncology and other serious diseases by advancing real-world care. By marrying clinical expertise with smart technologies, we transform data into evidence—and then into experience—in collaboration with our network of partners, who are committed to improving patients’ lives through community health systems. Together, we connect comprehensive patient insights to our network, to empower our partners in driving real impact and improving access to high-quality care. For more information, visit www.syapse.com.
About Genesis Research
Genesis Research is an international health economics and outcomes research and real-world evidence research organization that supports the life sciences industry. As a leader in evidence strategy, generation and communication, the company also supports pharmaceutical and biotech clients with tech-enabled, dedicated partnerships delivered via a unique engagement model that enables life sciences companies to address complex needs with unmatched timeliness and quality. For more information, visit www.genesisrg.com.
For more information, please contact:
Genesis Research: Richard Chumbley, Marketing Director rchumbley@genesisrg.com
Syapse: Christian Edgington, Media & Engagement cedgington@realchemistry.com
This content was provided by Genesis Research Group
Company Details
Latest Content from Genesis Research Group
MFN Pricing Is Moving Fast – Here’s What Matters
With GENEROUS, GUARD, and GLOBE all released since December, 185 pages of policy will materially impact U.S. drug pricing — and yes, it's a lot to digest. In a new...
ISPOR’s 2026–2027 HEOR Trends report: The Era of Evidence Judgment
In response to ISPOR’s recently published 2026-2027 HEOR Trends, David Miller, CEO, Genesis Research Group, suggests that we’re no longer being evaluated on our ability to produce data, but on...
Tim Wright Updates ISPOR Europe MFN Pricing Presentation in New Interview
At ISPOR Europe in Glasgow, there were literal queues around the block for Tim Wright's HEOR Theater presentation 'MFN Pricing: More Fun to Navigate – A European Roadmap to Success,' with potentially...
Genesis Research Group contributes strong scientific program to ISPOR Europe and warmly invites visitors to booth 212
Genesis Research Group is proud to be attending ISPOR Europe 2025 in Glasgow from 10-12th November with a strong scientific program that includes an HEOR Theater session, contributions to 10...
ISPOR hosts expert webinar exploring the value of ECAs for regulatory and HTA evidence needs
On Tuesday, October 7th, you are invited to join a Genesis Research Group-led webinar exploring the value of External Control Arm (ECA) studies. Gaining traction as part of evidence generation...
Dave W. Miller interviewed by Paige McGarry on the unique challenges faced by biotech companies
HealthEconomics.com interviews David W. Miller, CEO of Genesis Research Group, to discuss the unique challenges faced by biotech companies in evidence generation, market access, and stakeholder engagement.
Genesis Research Group Appoints Tim Wright as Executive Vice President, Access and Pricing
Genesis Research Group, a leading provider of tech-enabled real-world evidence (RWE), health economics and outcomes research (HEOR), and market access services, announces the appointment of Tim Wright as Executive Vice...
Navigating US market access analytics: A conversation with Ki Park
In the rapidly evolving landscape of healthcare and pharmaceutical market access, data analytics has become a critical component for making informed decisions. We sat down with Ki Park, our Vice...
Strategy. Insights. Access. Genesis Research Group outlines its integrated, data-driven solutions for US and global access and pricing.
In today’s rapidly evolving environment, US and global access and pricing decisions demand robust evidence, rigorous analysis, and strategic precision. Following Genesis Research Group's recent expansion of its real-world data...
Genesis Research Group announces inaugural membership of ISPOR Corporate Partnership Program
Genesis Research Group, a pioneer of tech-enabled real-world evidence (RWE), health economics and outcomes research (HEOR), and market access services, today announces it has joined selected organizations as an inaugural...